Related Experiment Videos
Distribution and excretion of 7-N-(p-hydroxyphenyl)-mitomycin C in normal mice
Abstract:
Tissue distribution, excretion and stability of 7-N-(p-hydroxyphenyl)-mitomycin C (M-83) in normal mice were compared with those of mitomycin C (MMC) by microbiological assay. M-83 was more rapidly inactivated by mouse liver homogenate in vitro than MMC. MMC could not be detected by thin-layer chromatography-bioautography in the reaction mixture of M-83 incubated with mouse liver homogenate, or in the mouse urine. Both M-83 and MMC exhibited biphasic serum elimination characteristics after iv bolus injection. When these compounds were administered at their approximate LD50 (M-83, 20 mg/kg; MMC, 8 mg/kg) iv into mice, their half-lives were 17.9 and 19.8 min, respectively. However, the half-life of M-83 (10.2 mg/kg) after iv bolus injection was 7.5 min and was shorter than that of MMC (8 mg/kg) at the molar equivalent dose. In ip administration of an approximate LD50, M-83 and MMC exhibited similar drug absorption and elimination patterns. When both compounds were administered iv at the approximate LD50, the 24-hr urinary recoveries of unchanged M-83 and MMC were 2.85 and 19.26%, respectively. The distribution of M-83 in various tissues was similar to that of MMC.
Insights
7-N-(p-hydroxyphenyl)-mitomycin C (M-83) shows faster inactivation and lower urinary excretion than mitomycin C (MMC) in mice. Despite similar tissue distribution, M-83 has a shorter serum half-life at molar equivalent doses.
Area of Science:
- Pharmacology
- Drug Metabolism
- Toxicology
Background:
- Mitomycin C (MMC) is a potent chemotherapeutic agent.
- Understanding the pharmacokinetics of MMC analogs is crucial for developing safer and more effective treatments.
- 7-N-(p-hydroxyphenyl)-mitomycin C (M-83) is a novel analog of MMC.
Purpose of the Study:
- To compare the tissue distribution, excretion, and stability of M-83 with MMC in normal mice.
- To evaluate the pharmacokinetic profiles of M-83 and MMC after intravenous and intraperitoneal administration.
- To determine the metabolic fate and elimination pathways of M-83 in vivo.
Main Methods:
- Microbiological assay was used to quantify M-83 and MMC.
- In vitro inactivation studies were performed using mouse liver homogenate.
- Thin-layer chromatography-bioautography was employed to detect unchanged drugs.
- Serum elimination kinetics were analyzed after intravenous bolus injection.
- Urinary recovery of unchanged drugs was measured over 24 hours.
Main Results:
- M-83 was inactivated more rapidly by mouse liver homogenate in vitro compared to MMC.
- MMC was not detected in the reaction mixture of M-83 incubated with liver homogenate or in mouse urine.
- Both M-83 and MMC exhibited biphasic serum elimination after intravenous administration.
- At approximate equipotent doses, M-83 demonstrated a shorter serum half-life (7.5 min) than MMC (19.8 min).
- Intraperitoneal administration showed similar absorption and elimination patterns for both drugs.
- 24-hour urinary recovery of unchanged M-83 (2.85%) was significantly lower than that of MMC (19.26%).
- Tissue distribution patterns of M-83 were comparable to those of MMC.
Conclusions:
- M-83 exhibits more rapid metabolic inactivation and lower urinary excretion than MMC in mice.
- The shorter serum half-life of M-83 at molar equivalent doses suggests potential differences in efficacy and toxicity.
- Further studies are warranted to elucidate the clinical implications of these pharmacokinetic differences.